AU2013203247A1 - Compositions and methods for nanopolymer-based nucleic acid delivery - Google Patents

Compositions and methods for nanopolymer-based nucleic acid delivery Download PDF

Info

Publication number
AU2013203247A1
AU2013203247A1 AU2013203247A AU2013203247A AU2013203247A1 AU 2013203247 A1 AU2013203247 A1 AU 2013203247A1 AU 2013203247 A AU2013203247 A AU 2013203247A AU 2013203247 A AU2013203247 A AU 2013203247A AU 2013203247 A1 AU2013203247 A1 AU 2013203247A1
Authority
AU
Australia
Prior art keywords
nucleic acid
composition
poly
acetylglucosamine
deacetylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013203247A
Other languages
English (en)
Inventor
Marina V. Demcheva
John N. Vournakias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marine Polymer Technologies Inc
Original Assignee
Marine Polymer Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Polymer Technologies Inc filed Critical Marine Polymer Technologies Inc
Publication of AU2013203247A1 publication Critical patent/AU2013203247A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2013203247A 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery Abandoned AU2013203247A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41086310P 2010-11-06 2010-11-06
US61/410,863 2010-11-06
US41135810P 2010-11-08 2010-11-08
US61/411,358 2010-11-08
AU2011323078A AU2011323078B2 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2011323078A Division AU2011323078B2 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery

Publications (1)

Publication Number Publication Date
AU2013203247A1 true AU2013203247A1 (en) 2013-05-09

Family

ID=46025153

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013203247A Abandoned AU2013203247A1 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery
AU2011323078A Ceased AU2011323078B2 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery
AU2016201640A Abandoned AU2016201640A1 (en) 2010-11-06 2016-03-15 Compositions and methods for nanopolymer-based nucleic acid delivery

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2011323078A Ceased AU2011323078B2 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery
AU2016201640A Abandoned AU2016201640A1 (en) 2010-11-06 2016-03-15 Compositions and methods for nanopolymer-based nucleic acid delivery

Country Status (10)

Country Link
US (3) US20130287853A1 (enExample)
EP (1) EP2635261B1 (enExample)
JP (2) JP6029591B2 (enExample)
CN (2) CN103282024A (enExample)
AU (3) AU2013203247A1 (enExample)
CA (1) CA2816999A1 (enExample)
ES (1) ES2763432T3 (enExample)
IL (1) IL226170B (enExample)
MX (1) MX358050B (enExample)
WO (1) WO2012061803A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2918452T3 (es) 2007-02-19 2022-07-15 Marine Polymer Tech Inc Composiciones hemostáticas y regímenes terapéuticos
NZ703163A (en) 2010-04-15 2016-06-24 Marinepolymer Tech Inc Anti-bacterial applications of poly-n-acetylglucosamine nanofibers
CN103282024A (zh) * 2010-11-06 2013-09-04 海洋聚合物技术公司 用于纳米聚合物基核酸递送的组合物和方法
EP2696680B1 (en) 2011-04-15 2018-11-28 Marine Polymer Technologies, Inc. Treatment of hsv infections with poly-n-acetyl glucosamine nanofibers
CA2968160C (en) * 2016-05-31 2024-01-02 Sachiko Sato Use of n-acetylglucosamine and derivatives thereof to treat muscle disorders
EP3693024A1 (en) * 2019-02-05 2020-08-12 Altona Diagnostics GmbH Control for nucleic acid preparation and/or detection methods
IT202200004574A1 (it) * 2022-03-10 2023-09-10 Sergio Ammendola Nanoparticelle di N-acetilglucosammina e loro applicazioni

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB0126923D0 (en) * 2001-11-09 2002-01-02 Procter & Gamble Chitosan compositions
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
JP2005281239A (ja) * 2004-03-30 2005-10-13 Nippon Zeon Co Ltd 鶏用ｄｎａワクチン
US20060105049A1 (en) * 2004-11-12 2006-05-18 Valorisation Recherche Hscm & Universite De Montreal Folic acid-chitosan-DNA nanoparticles
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
WO2008039390A2 (en) * 2006-09-22 2008-04-03 Government Of The Usa., Dept. Of Health & Human Services Compositions and methods for chitosan enhanced immune response
KR100882611B1 (ko) * 2006-11-14 2009-02-12 주식회사 키토라이프 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법
WO2008094659A2 (en) * 2007-01-31 2008-08-07 Allergan, Inc. Novel biomaterials for ocular drug delivery and a method for making and using same
US20100086613A1 (en) * 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same
US20100105139A1 (en) * 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
CA2833415A1 (en) * 2010-05-10 2011-11-17 Corporation De L'ecole Polytechnique De Montreal Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
CN103282024A (zh) * 2010-11-06 2013-09-04 海洋聚合物技术公司 用于纳米聚合物基核酸递送的组合物和方法

Also Published As

Publication number Publication date
MX358050B (es) 2018-08-03
ES2763432T3 (es) 2020-05-28
CN103282024A (zh) 2013-09-04
IL226170B (en) 2018-11-29
US20130287853A1 (en) 2013-10-31
US20170128382A1 (en) 2017-05-11
EP2635261A2 (en) 2013-09-11
CA2816999A1 (en) 2012-05-10
WO2012061803A3 (en) 2012-08-16
AU2016201640A1 (en) 2016-04-07
AU2011323078A1 (en) 2013-05-02
JP2014500250A (ja) 2014-01-09
JP6029591B2 (ja) 2016-11-24
WO2012061803A2 (en) 2012-05-10
CN108743562A (zh) 2018-11-06
JP2016164181A (ja) 2016-09-08
MX2013005016A (es) 2014-03-12
EP2635261A4 (en) 2014-09-17
US20230157971A1 (en) 2023-05-25
AU2011323078B2 (en) 2016-04-14
EP2635261B1 (en) 2019-10-23
IL226170A0 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
US20230157971A1 (en) Compositions and methods for nanopolymer-based nucleic acid delivery
US12442005B2 (en) Artificial nucleic acid molecules for improved protein expression
ES2384113T3 (es) Modificación del ARN, que produce unas estabilidad de transcripción y eficiencia de traducción aumentadas
JP6827488B2 (ja) 鼻内送達のための方法および組成物
CN109328233B (zh) 反式复制rna
Jechlinger Optimization and delivery of plasmid DNA for vaccination
US20250213599A1 (en) Formulation for administration of rna
Josefsberg et al. Vaccine process technology
Běláková et al. DNA vaccines: are they still just a powerful tool for the future?
Lin et al. Induction of robust immune responses by CpG-ODN-loaded hollow polymeric nanoparticles for antiviral and vaccine applications in chickens
EP2022853A1 (en) Freeze-dried product for transferring nucleic acid, oligonucleic acid or derivative thereof
US20220145309A1 (en) Yeast-Based Oral Vaccination
AU755126B2 (en) Stable gene preparations
Jones et al. Biomaterials at the interface of nano-and micro-scale vector–cellular interactions in genetic vaccine design
Ongkudon et al. Mitigating the looming vaccine crisis: production and delivery of plasmid-based vaccines
RU2834627C1 (ru) ДНК-последовательности, предназначенные для вакцинации человека и животных от развития заболевания, вызванного штаммами Brucella
Wang Control and Optimization of Immune Responses Induced by Nucleic Acid Vaccines
Chartrain et al. The production of plasmid DNA vaccine in Escherichia coli: a novel bacterial-based vaccine production platform
CN120586073A (zh) DOTAP-CL修饰的脂质纳米颗粒及其在递送mRNA疫苗中的应用
Te-hui et al. Gene Delivery Using Physical Methods
HK40004174A (en) Trans-replicating rna

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted